The prognosis of autosomal recessive polycystic kidney disease is known to correlate with genotype. The presence of two truncating mutations in the PKHD1 gene encoding the fibrocystin protein is associated with neonatal death while patients who survive have at least one missense mutation. To determine relationships between genotype and renal and hepatic abnormalities we correlated the severity of renal and hepatic histological lesions to the type of PKHD1 mutations in 54 fetuses (medical pregnancy termination) and 20 neonates who died shortly after birth. Within this cohort, 55.5% of the mutations truncated fibrocystin. The severity of cortical collecting duct dilatations, cortical tubule and glomerular lesions, and renal cortical and hepatic portal fibrosis increased with gestational age. Severe genotypes, defined by two truncating mutations, were more frequent in patients of less than 30 weeks gestation compared to older fetuses and neonates. When adjusted to gestational age, the extension of collecting duct dilatation into the cortex and cortical tubule lesions, but not portal fibrosis, was more prevalent in patients with severe than in those with a non-severe genotype. Our results show the presence of two truncating mutations of the PKHD1 gene is associated with the most severe renal forms of prenatally detected autosomal recessive polycystic kidney disease. Their absence, however, does not guarantee survival to the neonatal period.
The prognosis of autosomal recessive polycystic kidney disease is known to correlate with genotype. The presence of two truncating mutations in the PKHD1 gene encoding the fibrocystin protein is associated with neonatal death while patients who survive have at least one missense mutation. To determine relationships between genotype and renal and hepatic abnormalities we correlated the severity of renal and hepatic histological lesions to the type of PKHD1 mutations in 54 fetuses (medical pregnancy termination) and 20 neonates who died shortly after birth. Within this cohort, 55.5% of the mutations truncated fibrocystin. The severity of cortical collecting duct dilatations, cortical tubule and glomerular lesions, and renal cortical and hepatic portal fibrosis increased with gestational age. Severe genotypes, defined by two truncating mutations, were more frequent in patients of less than 30 weeks gestation compared to older fetuses and neonates. When adjusted to gestational age, the extension of collecting duct dilatation into the cortex and cortical tubule lesions, but not portal fibrosis, was more prevalent in patients with severe than in those with a non-severe genotype. Our results show the presence of two truncating mutations of the PKHD1 gene is associated with the most severe renal forms of prenatally detected autosomal recessive polycystic kidney disease. Their absence, however, does not guarantee survival to the neonatal period. Autosomal recessive polycystic kidney disease (ARPKD) is characterized by the association of bilateral renal cystic disease and congenital hepatic fibrosis (CHF). ARPKD can involve a wide spectrum of clinical phenotypes, correlated in part with the age at presentation. 1, 2 The most severe forms of the disease, accounting for about 40% of cases, are detected early during gestation by ultrasonography that shows tremendously enlarged echogenic kidneys and oligohydramnios. If medical pregnancy termination is not performed, most of these infants die in the perinatal period from respiratory insufficiency due to pulmonary hypoplasia. But over half of the patients are detected late during pregnancy or are undetected prenataly and survive the perinatal period. More than half of them require kidney transplantation before reaching 20 years of age, whereas others have preserved renal function until adulthood. [1] [2] [3] [4] [5] CHF complications such as bleeding esophageal varices and cholangitis, may occur as soon as early childhood or during adulthood, sometimes years after renal transplantation. 6 ARPKD is caused by mutations in the PKHD1 gene that encodes the protein fibrocystin expressed in the primary cilia and the basal body of renal and bile ducts epithelial cells. [7] [8] [9] [10] [11] [12] [13] [14] Presently, 303 mutations of PKHD1 have been reported in ARPKD patients (http://www.humgen.rwth-aachen.de/). Several studies have shown that truncating mutations were present in about 55% of the most severe cases-medical pregnancy termination or early demise patients-but only in about 20% of live patients. 10, [15] [16] [17] [18] [19] [20] [21] [22] But no study ever analyzed the relationship between the severity of histological renal and hepatic lesions and the genotype.
The aim of our study was to investigate the genotype--phenotype correlations in a cohort of 74 fetuses or early demise patients with ARPKD, by analyzing the relations between the histological severity of renal and hepatic lesions and the type of PKHD1 mutations.
RESULTS

Renal and hepatic histology
According to inclusion criteria, dilatation of medullar collecting ducts, radially oriented, was present in the 73 available kidney specimens. Portal fibrosis and increased number and dilatation of bile ducts were present in the 61 available liver specimens.
The severity of renal lesions was evaluated according to five criteria: (i) The extension in the cortex of the dilatation of collecting ducts, which was graded as either absent, or partial if present only in the inner part of the cortex, with preservation of the nephronic zone and the superficial rows of developing nephrons, or global if affecting the whole cortex up to the subcapsular areas ( Figure 1 ). (ii) The presence of degenerative changes of cortical tubules (proximal and distal convoluted tubules) that may be dedifferentiated, atrophic or reduced in number. According to their extension and severity, lesions were classified as grade 1: absent of significant changes or mild tubular lesions mostly seen in the deep cortex; grade 2: moderate but diffuse tubular lesions; grade 3: massive reduction in the number of nephrons with complete disappearance of proximal tubules (Figure 2a In the liver, the severity of lesions was categorized according to the importance of portal fibrosis, classified as grade 1: presence of mild fibrosis, only touching the largest portal tracts; grade 2: fibrosis of all portal tracts, whatever their size; grade 3: massive fibrosis leading to marked enlargement of all portal tracts with fibrous extensions bridging adjacent portal areas ( Figure 3) .
Extension of collecting duct dilatation in the cortex was absent in three cases (4%), partial in 35 cases (48%) and global in 35 cases (48%). Cortical tubule lesions were grade 1 in 19 cases (26%), grade 2 in 29 cases (40%), and grade 3 in 25 cases (34%). Proximal tubule dilatation was observed in 26 cases (37%). Glomerular lesions were present in 44 cases (62%) and cortical fibrosis in 24 cases (34%) ( Table 1 and  Supplementary Table S1 ). Portal fibrosis was grade 1 in 5 cases (8%), grade 2 in 41 cases (67%), and grade 3 in 15 cases (25%) ( Table 1 and Supplementary Table S1 ).
The degree of extension of collecting duct dilatation within the cortex was significantly correlated with the severity of cortical tubule lesions, glomerular lesions and cortical fibrosis. Proximal tubule dilatation was the only lesion that was significantly more frequent when collecting duct dilatation in the cortex was absent or partial compared with global ( Table 2 ). There was also a correlation, close to significance, between the extension of collecting duct dilatation within the cortex and the grade of portal fibrosis ( Table 2) .
The degree of extension of collecting duct dilatation within the cortex, the severity of cortical tubule and glomerular lesions significantly increased with gestational age (GA). A similar trend was observed between the severity of cortical fibrosis and GA. Proximal tubule dilatation was the only lesion that was significantly more frequent when GA was p30 weeks compared with 430 weeks. The grade of portal fibrosis also significantly increased with GA (Table 1) . Supplementary  Table S1 .
The impact of GA on histological lesions is illustrated in Figure 4 , showing renal and hepatic lesions in two consecutive affected foetuses of the same family (patient 54), at 27 weeks and 13 weeks of GA, respectively.
PKHD1 mutations
A total of 128 mutations were detected, four patients (no. 17, 36, 59, and 60) had three mutations (Supplementary Table S2 ). Table S1 .
Seventy-one mutations (55.5%) were truncating with 44 frameshifting small deletions/insertions/duplications, 24 nonsense mutations and three splice mutations with exon skipping, leading to out of frame fusion of exons. Fifty-four mutations (42.2%) were missense mutations. One mutation was a missense mutation associated with an in-frame insertion of six bases in exon 16, one mutation was an inframe deletion of 42 bases in exon 30 and one mutation was a one-base deletion in exon 67 leading to the change of the last 12 amino acids of the fibrocystin, the abolition of the stop codon and the addition of nine amino acids (Supplementary  Tables S2 and S3 ). Parent DNA analysis in the four patients with three mutations showed that the co-inherited mutations were always missense mutations (Supplementary Table S2) .
We observed eight patients with homozygous mutations, implicating truncating mutations in all except one (Supplementary Table S2 ). When parents DNAs were available (five cases), the homozygous character of the mutation was confirmed by testing both parents. In the three remaining cases, intragenic SNPs and intra and flanking extragenic microsatellites showed a homozygous pattern (data not shown), indicating that the mutation was either homozygous, or in combination with a large PKHD1 deletion.
Mutations were observed all along the gene, scattered in 41 exons. However, three mutations were recurrent: the T36M missense (n ¼ 13) in exon 3 and the frameshifts c.5895dupA (L1966fs) (n ¼ 9) in exon 36 and c.9689delA (D3230fs) (n ¼ 13) in exon 58 (Supplementary Tables S2 and S3) . Furthermore, the screening of 6 exons (3, 32, 36, 57, 58, and 61) allowed the identification of 51% of mutations. Table S1 . 9, 14, 18, 19, 22, and 34) led to a detection rate of 64%.
Genotype-phenotype correlation analysis
For this analysis, truncating mutations (T) (nonsense, frameshift and splice mutations) and non-truncating mutations (NT) (missense mutations and diverse in-frame modifications) were considered (Supplementary Table S2 ). According to the fact that the disease is recessive with a loss of function of the fibrocystin protein, we considered genotype as severe when two truncating mutations were present (T/T, 21 patients) and non-severe if at least one NT mutation was present (41 patients including 20 with NT/T, 12 with NT/NT and 9 with NT/non identified (NI) mutations). Patients with T/NI (nine patients) or NI/NI (three patients) mutations were excluded for the genotype-phenotype correlation analysis as they could have undetected severe mutations such as an intragenic or large PKHD1 deletion, not screened in our study. Severe genotype was significantly more frequent in fetuses that underwent medical pregnancy termination at 30 weeks of GA or less (53%) compared to those with GA over 30 weeks (16%, including three medical pregnancy terminations and two post-natal deaths). Conversely, the majority of patients who underwent medical pregnancy termination after 30 weeks of GA or who died after birth had non-severe genotype (Table 3) . It is interesting to note that 10 different missense mutations (T36M, I222V, R328G, T1300K, C1692Y, P1791L, R2370G, W2736G, I2957T, and R3240K) were identified among the 16 patients with non-severe genotype who died after birth.
When GA was not taken into account, no correlation was found between the severity of genotype and any of the histological criteria of severity (Supplementary Table S4 ). However, when adjusted to GA, the degree of extension of collecting duct dilatation in the cortex was significantly more important in the patients with severe genotype compared to those with non-severe genotype. The grade of cortical tubule lesions adjusted to GA was also more important in the patients with severe genotype than in those with non-severe genotype (Table 4) . Proximal tubule dilatation, glomerular lesions, cortical fibrosis, and hepatic fibrosis adjusted on GA were not significantly different between the two groups of genotype (Table 4) .
DISCUSSION
This is the first series of ARPKD patients who analyzed the genotype-phenotype correlations via the relations between the severity of renal and hepatic histological lesions and PKHD1 mutations.
The severity of the disease in this series of prenatally detected ARPKD was confirmed by the association of severe cortical lesions with the typical dilatation of collecting ducts in the medulla. Extension to the cortex of collecting duct dilatation was observed in 96% of patients and cortical tubule lesions grade 2 or 3 in 74% of the patients. Similarly, portal fibrosis grade 2 or 3 was present in 92% of patients (Table 1  and Supplementary Table S1 ). It is generally considered that cortical lesions in ARPKD are the consequence of compression by the cystic collecting ducts extending to the cortex. Our series confirms that the severity of cortical tubule lesions, glomerular lesions, and cortical fibrosis were significantly correlated with the degree of extension of collecting duct dilatation within the cortex (Table 2) . It is interesting to note that a correlation close to significance was also found between the degree of portal fibrosis and the extension of collecting ducts in the renal cortex, suggesting that renal and hepatic involvement have a parallel severity in the most severe forms of ARPKD detected prenatally. A prerequisite before investigating the correlations between histological phenotype and genotype was to analyze the effect of GA on the severity of histological lesions. Our study confirmed that the degree of extension of collecting duct dilatation within the renal cortex, the severity of cortical tubule lesions, glomerular lesions, cortical fibrosis, and portal fibrosis increased significantly with GA (Table 1) , a logical issue, but not demonstrated previously in humans, even in the seminal studies of Osathanonah and Potter. 23 The only histological abnormality, which we observed to be more frequent when GA was p30 weeks compared with 430 weeks was the dilatation of proximal tubules (Table 1) , which also was more frequent when the extension of collecting duct dilatation within the cortex was absent or partial compared with global ( Table 2 ). Dilatation of proximal tubules has been reported as an early lesion, preceding collecting duct cystic dilatation in human ARPKD fetuses 24 and several mouse models of ARPKD. [25] [26] [27] [28] [29] Ward et al. 9 have shown that the PKHD1 protein fibrocystin is expressed in embryonic human kidneys not only in the branching ureteric ducts and collecting ducts, but also, with a weaker intensity, in the developing nephrons. In addition, expression of fibrocystin has been shown in human adult 12 and in mouse 30 proximal tubules.
In this series of severe ARPKD, the mutation detection rate was 83.8%, a proportion similar to that reported in series including the most severe forms of the disease. 10, [15] [16] [17] [18] Two mutations were identified in 71.6% of patients, one in 24.3%, and none in three patients (2.4%). This repartition is similar to that reported by Bergmann et al. 16 in families requesting prenatal diagnosis after having lost a child with severe ARPKD. Among the 75 different mutations, 41 (54.6%) were unreported, expending the spectrum of known PKHD1 mutations from 303 to 344. We found that the proportion of truncating mutations was around 55%, exactly as in series of patients with early demise, compared with 21-23% in series of living patients. 10, [15] [16] [17] 20, 21 Most patients with 2 truncating mutations die in the neonatal period. 10, 15, 17 Overall, at least one amino acid substitution mutation is necessary for survival in the neonatal period. 21 In our series, severe genotypes, characterized by two truncating mutations, predominated in the forms of ARPKD detected relatively early by prenatal ultrasonography. However, the 16 neonates with non-severe genotype died shortly after birth, indicating that the absence of two truncating mutations cannot be regarded as synonymous of a favorable prognosis ( Table 3 ).
Considering that most histological lesions increased with GA, it is not surprising that the intrinsic effect of mutations on histological lesions could not be evidenced when GA was not taken into account. On the other hand, after adjustment of histological lesions to GA, severe genotype was correlated with significantly more severe extension of collecting duct dilatation in the cortex and to a lesser degree, to more severe lesions of cortical tubules than non-severe genotype (Table 4) . However, the degree of proximal tubule dilatation, glomerular lesions, and cortical fibrosis, as well as the severity of portal fibrosis, adjusted to GA, were not significantly different according to the severity of the genotype (Table 4) . Although the cohort of patients was relatively important, it probably was insufficient for these criteria to reach statistical significance.
Additional events may interfere with the genotype-phenotype correlations. First, as allelic variation in gene expression is common in the human genome, 31 this can modulate the level of the various PKHD1 mutants, leading to differences in phenotypic expression. Second, modifier genes could also modulate the phenotype despite a unique PKHD1 genotype. 32 Interactions between PKHD1 and HNF1B, 33 the kinesin family member 12, 34 or PKD1 35 and PKD2, 36,37 the mouse orthologs of the genes linked to human autosomal dominant polycystic kidney disease, have been shown in animal models.
In conclusion, this study shows that the presence of two truncating mutations in PKHD1 is associated with the most severe renal lesions in patients with ARPKD detected early during pregnancy. However, patients with late prenatal detection, less severe histological lesions and without two truncating mutations may have postnatal demise, showing the limits of genetic screening to predict the clinical outcome.
MATERIALS AND METHODS
Criteria for the inclusion in the study Histological confirmation of the diagnosis of ARPKD/CHF was the prerequisite for inclusion. Histological criteria for ARPKD were: (i) fusiform dilatation of the collecting ducts, with a radial disposition from the calyx and medulla towards the cortex [38] [39] [40] (ii) CHF defined by portal fibrosis surrounding increased numbers of hyperplasic and ectatic biliary ducts, with normal hepatocellular histology. 39, 40 In a single patient without renal histology, the diagnosis of ARPKD relied on liver histology and the presence of PKHD1 mutations. Seventy-four patients representing 74 unrelated nuclear families were studied, including 54 fetuses (median GA at medical pregnancy termination: 28 weeks (14-37 weeks)), and 20 postnatal demise patients (median age at death, 20 days (1 day to 6 months)). Median GA for the whole cohort was 30 weeks. In the case of kindred (12 siblings, six pedigrees) or twins (four twins, two pedigrees), only the first propositus was included in the study because the comparison of histological data in the siblings of similar GA or twins did not indicate intrafamilial variability.
Father and mother's country of birth was France in 70 and 77% of cases, respectively. Other parents were of Italian (4%), Turkish (4%), Spanish (2%), Finish (1%), Algerian (1%), Lebanon (1%) or Chinese (1%) origin. Origin was unknown in 15% of parents.
Histological study
Renal specimens were available in 73 cases and liver specimens in 61, including the only patient with no renal tissue available. All specimens were collected during autopsy except one (post-mortem biopsy). They were fixed in 4% buffered formalin and embedded in paraffin. Special attention was paid for taking frontal corticomedullary sections of the kidney passing through the hilus allowing correct analysis of cystic structures. Five micrometer-thick sections were stained with trichrome, hematoxylin eosin safran or periodic acid of Schiff. Some of the samples were examined after Red Sirius staining of fibrosis, or after immunohistochemical-specific identification of collecting ducts (using anti-EMA antibody) or proximal tubules (using CD15 antibody). They were examined independently by three pathologists (ALD, MCG, and RB) for confirmation of the diagnosis and evaluation of the severity of kidney and liver lesions. The evaluation was concordant between the 3 pathologists in all cases except 4, leading to common re-examination of the slides of these patients.
PKHD1 mutation screening
For each patient, informed consent for genetic testing was obtained from both parents. Genomic DNA was isolated from the index cases using standard procedures on the following samples: amniotic fluid, chorionic villus, lung or liver tissue obtained during the autopsy, peripheral blood. GenomiPhi HY DNA amplification kit (GE Healthcare Europe GmbH, Orsay, France) was then used for the representational amplification of the extracted DNA as a limited amount of DNA was obtained from the original samples. Mutation screening was done for the 66 exons encoding the 4074 amino acids fibrocystin protein, including splice sites and at least 20 bp of intronic sequence. Preamplified DNA was subjected to PCR using the primer sets described in Supplementary Table S5 Table S5 ).
PKHD1 sequence analysis Sequence alignments were done using Seqscape software (Applied Biosystems). Classification of the DNA variations was done according to the Mutation Database for ARPKD from the Aachen University (http://www.humgen.rwth-aachen.de).
Newly described variations were classified as polymorphism or mutation as follows. Silent sequence variations (intronic or exonic) were classified as polymorphism. Truncating mutations (nonsense mutations, non in-frame insertions and deletions and consensus splice mutations (Supplementary Table S6 )) were classified as deleterious mutations. Finally, missense mutations were analyzed using six different tests: conservation between human, chimpanzee, dog, mouse, chicken, and frog PKHD1 protein 19 and five in silico protein structure and function prediction programs (Supplementary Table  S7 ). Sequence variation was considered as causing disease mutation when at least 50% of the performed tests predicted a pathological effect. Of the 13 unreported missense mutations, all but one (S1867G) fulfilled those criteria. However, as the S1867 is evolutionary conserved and the S1867N variation was reported as deleterious in a previous mutation study (http://www.humgen.rwthaachen.de), we considered S1867G as a missense mutation (Supplementary Table S7 ).
Statistical analysis
Results were expressed as median (range) for quantitative variables and numbers (percentages) for categorical variables. Associations between categorical variables were examined with w 2 , Fischer's exact test or trend w 2 statistics as appropriate. The study of relationships between severity of mutations and renal/hepatic lesion grades were adjusted on gestational age dichotomized at median value using Cochran-Mantel-Haenszel statistics. All tests were two-sided and values of o0.05 were considered statistically significant. All analyses were performed with SAS statistical package (SAS 9.1, SAS Inc., Cary, NC, USA).
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